| Objetive:Zhengshisanqisan was a empirical formula for traumasby oral administration developed by professor Zheng Huaixian, a martial artist and thelate famous Chinese medicine expert on orthopedics and traumatology of ChengduSport University. It was mainly used with a unique effect in clinical treatment for localswelling, pain, and dysfunction caused by acute closed soft tissue injury, especially foracute muscle, tendon, and ligament injury. However, it was still yet to be effectivelydeveloped and promoted due to a lack of systematic pharmacological andpharmacodynamic studies and clinical research.It had been proved in the pretest that Zhengshisanqisan had obvious therapeuticeffect. Based on this understanding, this thesis analyzed the toxicity ofZhengshisanqisan on renal cells through animal experiments in the hope thatexperimental basis was provided for the safe medication of Zhengshisanqisan in sportsinjuries and clinical orthopedics and that professor Zheng’s ideas and experiences couldbe passed on.Methods: Firstly,75SPF-class SD experimental rats (males) were randomlysorted into five groups, namely the blank control group (Group A, n=15), theLiaoyuanqilisan drug control group (Group B, n=15), the Zhengshisanqisanconventional-dose group (Group C, n=15), the Zhengshisanqisan medium-dose group(Group D, n=15), and the Zhengshisanqisan high-dose group (Group E, n=15). Secondly,drugs were given to all the drug groups once a day for21days, according to theconversion of the drug dose in humans and animals, while an equal amount of warmwater was given to the control groups once a day for21days. Moreover, on the7th,14th,and21st day, blood was extracted from rats of different groups, blood indicators weretested, their kidneys were weighed, kidney coefficients calculated, and specimens ofkidney tissues kept. And, the renal tissue injury in different groups with different doseswas observed in the light microscope. With the observation and testing of relevantindicators, this thesis discussed the toxicity of Zhengshisanqisan and Liaoyuanqilisan onthe rats’ renal cells and their interactions, so that experimental basis could be providedfor clinical medication safety.And the thesis achieved the following results:1. Three weeks after given drugs, therats’ appearance, behavior, responded to stimuli, mental status, appetite, feces, urine,back hair, skin color, nose, eyes, and oral cavity remained normal. In each group, ratsincreased in weight without any trace of toxic reactions.2. The renal biopsies on the7th,14th, and21st day showed that the renal capsule was complete and there was nopathological changes such as lumps, redness, edema, or atrophy. The renal cells of ratsof different groups were complete, and necrosis in renal cells was not found.3. Rats indifferent groups were weighed on the7th,14th, and21st day respectively and noobvious difference were found (P＞0.05).4. The kidneys of rats in different groupswere weighed on the7th,14th, and21st day respectively and no obvious differenceswere found (P＞0.05)5. The renal coefficients of rats in different groups werecalculated on the7th,14th, and21st day respectively and no obvious difference werefound (P＞0.05).6. blood of rats in different groups was extracted on the7th,14th, and21st day respectively after they were dosed, and the blood urea nitrogen (BUN) andcreatinine (Cr) were tested with no significant difference being found (P＞0.05).Conclusions:1. The experiment showed that large dose of Zhengshisanqisan in three weeksmade no significant difference in the weight of the rats.2. The medication safety was guaranteed when the Liaoyuanqilisan drug controlgroup was doses with conventional amount within three weeks. Within three weeks,Zhengshisanqisan dose groups and Liaoyuanqilisan drug control group witnessed no significant effect on and changes in renal tissue cells. Furthermore, the blood ureanitrogen (BUN) and creatinine (Cr) showed no significant changes. In conclusion, therewas no significant toxic difference in renal cell toxicology.3. With three weeks, the Zhengshisanqisan conventional-dose group, theZhengshisanqisan medium-dose group, and the Zhengshisanqisan high-dose groupremained safe. Therefore, these three different amounts of dose were suitable forclinical use. |
PDF Full Text Request